IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial
Liu Kai-yan1; Wang Yu1; Han Ming-zhe2,3; Huang He4; Chen Hu5; Liu Qi-fa6; Wang Jian-min7; Liu Ting8; Song Yong-ping9; Ma Jun10; Wu De-pei11; Zou Ping12; Huang Xiao-jun1
关键词valganciclovir cytomegalovirus infections hematopoitic stem cell transplantation
刊名CHINESE MEDICAL JOURNAL
2010-08-20
DOI10.3760/cma.j.issn.0366-6999.2010.16.008
123期:16页:2199-2205
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
资助者Hoffmann-La Roche AG (Grenzach-Wyhlen, Germany) ; Hoffmann-La Roche AG (Grenzach-Wyhlen, Germany)
研究领域[WOS]General & Internal Medicine
关键词[WOS]BONE-MARROW-TRANSPLANTATION ; IMMUNOCOMPROMISED PATIENTS ; INTRAVENOUS GANCICLOVIR ; ORAL VALGANCICLOVIR ; CMV INFECTION ; HOST-DISEASE ; RECIPIENTS ; PREVENTION ; BLOOD ; IMMUNODEFICIENCY
英文摘要

Background Despite its widespread use in the management of HIV-related cytomegalovirus (CMV) infection, there have been surprisingly few reports of the use of valganciclovir (VGC) in the post-allotransplant setting So far, no multi-center, non-crossover trial data have been available with the use of this drug as the primary pre-emptive The present study evaluated the efficacy and safety of VGC for preemptive therapy of CMV infection after allogeneic hematopoietic stem cell transplantation (HSCT).

Methods From January to April 2007, VGC was adopted in eleven centers in mainland China for pre-emptive therapy of CMV infection in consecutive patients undergoing allogeneic HSCT Allogeneic HSCT recipients were followed weekly via CMV pp65 antigenemia assay or real-time quantitative polymerase chain reaction (PCR) for detection of CMV-DNA Patients with a positive assay were treated with VGC, 900 mg PO. twice a day for 14 days followed by 900 mg P.O. once a day for 14 days after a negative result or the CMV-DNA load was lower.

Results A total of 54 patients (15 siblings, 28 mismatched related donors, 11 unrelated donors) had a positive assay treated with oral VGC The seroconversion rate was 89% (48/54) as confirmed by a negative assay, six patients failed oral VGC No significant toxicity was encountered No case of CMV disease was diagnosed in the responding patients with a median follow-up of 5.3 months after the drug administration

Conclusion Pre-emptive therapy of CMV viraemia with oral VGC is safe and effective in allogeneic HSCT

语种英语
所属项目编号ML20466
资助者Hoffmann-La Roche AG (Grenzach-Wyhlen, Germany) ; Hoffmann-La Roche AG (Grenzach-Wyhlen, Germany)
WOS记录号WOS:000281488300008
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/61430
专题北京大学第二临床医学院_血液科
作者单位1.Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
2.Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China
3.Peking Union Med Coll, Tianjin 300020, Peoples R China
4.Zhejiang Univ, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China
5.307 Hosp Peoples Liberat Army, Beijing 100071, Peoples R China
6.Nanfang Med Univ, Nanfang Hosp, Guangzhou 510515, Guangdong, Peoples R China
7.Second Mil Med Univ Peoples Liberat Army, Changhai Hosp, Shanghai 200433, Peoples R China
8.Sichuan Univ, W China Hosp, Chengdu 610041, Sichuan, Peoples R China
9.Henan Tumor Hosp, Zhengzhou 450008, Henan, Peoples R China
10.Harbin Inst Hematol & Oncol, Harbin 150010, Heilongjiang, Peoples R China
11.Soochow Univ, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China
12.Huazhong Univ Sci & Technol, Inst Hematol, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China
推荐引用方式
GB/T 7714
Liu Kai-yan,Wang Yu,Han Ming-zhe,et al. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial[J]. CHINESE MEDICAL JOURNAL,2010,123(16):2199-2205.
APA Liu Kai-yan.,Wang Yu.,Han Ming-zhe.,Huang He.,Chen Hu.,...&Huang Xiao-jun.(2010).Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial.CHINESE MEDICAL JOURNAL,123(16),2199-2205.
MLA Liu Kai-yan,et al."Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial".CHINESE MEDICAL JOURNAL 123.16(2010):2199-2205.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu Kai-yan]的文章
[Wang Yu]的文章
[Han Ming-zhe]的文章
百度学术
百度学术中相似的文章
[Liu Kai-yan]的文章
[Wang Yu]的文章
[Han Ming-zhe]的文章
必应学术
必应学术中相似的文章
[Liu Kai-yan]的文章
[Wang Yu]的文章
[Han Ming-zhe]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。